arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Biofrontera Inc.

BFRI
$0.82 ▼ -0.08 (-8.79%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
26 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
15
Health
Poor
Bearish
auto_awesome

Analytical Summary

Biofrontera Inc. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $10.6M
Dividend Yield —
Revenue Growth 32.9% ↗
Op. Margin -4.4% ↗
ROIC -9.1% ↗
FCF / Share $-0.13 ↘
Trailing P/E —
Price / Book 2.0x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

26-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$12.00M
↑ +32.9% —
Net Income Profit after all expenses
$-604.00K
↑ +88.7% —
Operating Margin Operating profit as % of sales
-4.4%
↑ +89.8% 8th
FCF / Share Free cash flow per share
$-0.13
↓ -1898.5% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↑
8
Returns ↑
9
Financial Health ↓
3
Cash Quality ↑
75

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 7 years · 26 quarters